EGFR and lung carcinoma: Lung cancer cells with acquired resistance to gefitinib or osimertinib (AZD9291) show EMT characteristics, with a decrease in E-cadherin and an increase in mesenchymal markers and stemness without any EGFR secondary mutations (55).